Skip to main content
RAFT: A CRISPR-Free RNA Trans-Splicing Platform for MYH7 Correction in Hypertrophic Cardiomyopathy

RAFT: A CRISPR-Free RNA Trans-Splicing Platform for MYH7 Correction in Hypertrophic Cardiomyopathy

Unmet Need Hypertrophic cardiomyopathy (HCM) is a common inherited heart disease affecting 1 in 500 individuals, frequently caused by mutations in the MYH7 gene. Current gene therapy approaches, including AAV-based gene replacement, face significant challenges…

Read More

Methods and compositions for enhancing viral and mRNA gene therapy with engineered RNA elements

Methods and compositions for enhancing viral and mRNA gene therapy with engineered RNA elements

Unmet Need An outstanding challenge in creating effective gene therapies, particularly those based on adeno-associated virus (AAV) and mRNA delivery platforms, is overcoming sub-optimal transgene expression. Inefficiencies in translation and stability of therapeutic gene products…

Read More

CRISPR-based antiviral treatment of coronavirus infections

CRISPR-based antiviral treatment of coronavirus infections

Unmet Need The global market for antiviral drugs is a large one, topping $60B, and is getting larger due to the ongoing COVID-19 pandemic. Spurred on by a $3B investment from the U.S. government into…

Read More

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us